Today Novartis offered 2.1 Billion for this Company. The lead compound is an injection and a psma targeted radiotherapy for refractory cr prostate cancer. Some nasty side effects with it. How does this compare to valuation appropriate for Zenith prostate program with potentially much larger market opportunity ?